As of May 29, 2025, Tanke Biosciences Corp (TNBI) reports a Current Ratio of 1.85.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Tanke Biosciences Corp's Current Ratio
Over recent years, Tanke Biosciences Corp's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2012-12-31 | 1.85 |
| 2011-12-31 | 5.33 |
| 2010-12-31 | 3.19 |
| 2009-12-31 | - |
| 2008-12-31 | 0.04 |
This slight upward trend highlights how Tanke Biosciences Corp manages its short-term assets and liabilities over time.
Comparing Tanke Biosciences Corp's Current Ratio to Peers
To better understand Tanke Biosciences Corp's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Tanke Biosciences Corp (TNBI) | 1.85 |
| Neurobiological Technologies Inc (NTII) | 22.01 |
| Hanyuan Biotech International Inc (TNPH) | 14.21 |
| Cardiva Medical Inc (IPO-CARI) | 5.08 |
| Jakroo Inc (JKRO) | 4.53 |
| QRS Music Technologies Inc (QRSM) | 4.24 |
Compared to its competitors, Tanke Biosciences Corp's Current Ratio is about average compared to peers, reflecting balanced short-term asset management.